This pharma stock just got whacked — there’s still a major catalyst ahead
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time ...
Tag: Novo Nordisk A/S
Novo Nordisk shares rise 8% after Wegovy obesity pill has ‘solid’ launch
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026.George Frey | Bloomberg ...
Behind Anthropic’s stunning growth is a sibling team that may hold the key to generative AI
SAN FRANCISCO — Daniela Amodei has an energy that's hard to place — warm, unhurried, immediately present. She swept into ...
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, ...
Nine of the largest pharma companies ink deals with Trump to lower drug prices
U.S. President Donald Trump speaks during an event in the Roosevelt Room of the White House December 19, 2025 in ...
Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug ...
Millions more Americans could access obesity drugs after Trump’s deals with Eli Lilly, Novo Nordisk
US President Donald Trump makes an announcement in the Oval Office of the White House in Washington, DC on Nov. ...
Week in review: The Nasdaq’s worst week since April, three trades, and earnings
It was a terrible start to November on Wall Street. The tech-heavy Nasdaq sank just over 3% in its worst ...
Where the blockbuster weight loss drug market stands today — and what’s coming next
A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by ...
Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to cut the ...
